Loading...
•
Dec 31, 2023
OPKO Health Q4 2023 Earnings Report
OPKO Health's financial performance declined due to decreased revenues and increased operating losses, but advancements were made in the product pipeline and approvals were received in China.
Key Takeaways
OPKO Health reported a decrease in consolidated total revenues to $181.9 million, compared to $185.4 million for the same period in 2022. The operating loss increased to $69.1 million, compared to $55.3 million in the prior year. Net loss was $65.5 million, or $0.09 per share, compared to a net loss of $85.2 million, or $0.11 per share, for the 2022 quarter.
Pharmaceutical revenue increased to $43.0 million, driven by international operations and RAYALDEE sales.
Diagnostics revenue decreased to $124.2 million due to lower clinical test reimbursement and COVID-19 testing volume.
Operating loss increased to $69.1 million, impacted by non-recurring expenses and revenue adjustments in the diagnostics segment.
ModeX advanced its antiviral and immune-oncology product pipeline.
Revenue by Segment
Forward Guidance
OPKO's senior management will provide a business update, discuss fourth quarter financial results, provide financial guidance and answer questions during a conference call and audio webcast today beginning at 4:30 p.m. Eastern time.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...